title: Mycobacterium marinum: an increasingly common opportunistic infection in patients on infliximab.
authors.forename: Jason
authors.initials: J
authors.lastname: Ferreira
authors.forename: Jared
authors.initials: J
authors.lastname: Grochowsky
authors.forename: Douglas
authors.initials: D
authors.lastname: Krakower
authors.forename: Peter
authors.initials: P
authors.lastname: Zuromskis
authors.forename: Rachel
authors.initials: R
authors.lastname: Baden
authors.forename: Adam S
authors.initials: AS
authors.lastname: Cheifetz
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000209:etiology* / Q000276:immunology*; D019910:Mycobacterium marinum; D009894:Opportunistic Infections; D017192:Skin Diseases, Bacterial / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab